Immunogen CFO Gregory Perry Sells 18,337 Shares (IMGN)
Immunogen (NASDAQ:IMGN) CFO Gregory Perry unloaded 18,337 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $17.82, for a total value of $326,765.34. The sale was disclosed in a document filed with the SEC, which is available at this link.
A number of analysts have recently weighed in on IMGN shares. Analysts at Jefferies Group reiterated a “buy” rating on shares of Immunogen (NASDAQ:IMGN) in a research note to investors on Monday. They now have a $21.00 price target on the stock. Separately, analysts at Leerink Swann initiated coverage on shares of Immunogen (NASDAQ:IMGN) in a research note to investors on Wednesday, September 4th. They set an “outperform” rating and a $24.00 price target on the stock. Finally, analysts at Roth Capital initiated coverage on shares of Immunogen (NASDAQ:IMGN) in a research note to investors on Monday, August 26th. They set a “buy” rating and a $19.00 price target on the stock.
One analyst has rated the stock with a sell rating, five have issued a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $17.70.
Shares of Immunogen (NASDAQ:IMGN) traded down 2.08% on Wednesday, hitting $17.87. The stock had a trading volume of 406,106 shares. Immunogen has a 52-week low of $10.85 and a 52-week high of $20.25. The stock’s 50-day moving average is $17.29 and its 200-day moving average is $16.65. The company’s market cap is $1.521 billion.
Immunogen (NASDAQ:IMGN) last issued its quarterly earnings data on Friday, August 2nd. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.04. The company had revenue of $3.83 million for the quarter, compared to the consensus estimate of $3.44 million. During the same quarter in the previous year, the company posted ($0.29) earnings per share. The company’s revenue for the quarter was up 29.8% on a year-over-year basis. On average, analysts predict that Immunogen will post $-0.85 earnings per share for the current fiscal year.
ImmunoGen, Inc (NASDAQ:IMGN) develops targeted, antibody-based therapeutics for the treatment of cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.